# US Glioblastoma Market

> US Glioblastoma Market Research Report: Size, Share, Trend Analysis By Treatment Type (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By Drug Type (Temozolomide, Bevacizumab, Carmustine, Nivolumab, Lomustine), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy) and By End Users (Hospitals, Clinical Research Organizations, Homecare Settings) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.94%
- **2024:** $ 714.14 Million
- **2025:** $ 756.56 Million
- **2035:** $ 1,347.24 Million
- **Key Players:** Bristol-Myers Squibb (US), Roche (CH), Merck & Co (US), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Regeneron Pharmaceuticals (US), Pfizer (US)

**Report ID:** MRFR/HC/16490-CR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** January 28, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-glioblastoma-market-18018

---

## Market Summary

## **US Glioblastoma Market Overview:**

As per MRFR analysis, the US Glioblastoma Market Size was estimated at 561.75 (USD Million) in 2023.The US Glioblastoma Market Industry is expected to grow from 594.44 (USD Million) in 2024 to 1,025.18 (USD Million) by 2035. The US Glioblastoma Market CAGR (growth rate) is expected to be around 5.079% during the forecast period (2025 - 2035).

### **Key US Glioblastoma Market Trends Highlighted**

The US Glioblastoma Market is experiencing several significant trends driven by advancements in research and technology. Growing awareness and advocacy surrounding brain cancer have increased both funding and support for research efforts, leading to innovations in treatment options. The rise of personalized medicine, which tailors treatments to individual genetic profiles, represents a promising shift in oncology, allowing for more effective targeting of glioblastoma. Moreover, the development and approval of new therapies, such as immunotherapy and targeted therapies, are ongoing, providing patients with alternative options that may improve survival rates.

As new technologies develop, opportunities within the US Glioblastoma Market continue to grow. There is a synergistic relationship between government, academia, and business which promotes innovation. For example, the National Cancer Institute supports and performs clinical trials for the development of treatment options for glioblastoma that require specialized clinical research. In addition, a focus on more remote detection methods of identification creates another opportunity for growth since detecting glioblastoma earlier on would greatly improve treatment success. There is a noticeable shift towards the use of technology in health management in relation to chronic illnesses such as cancer.

Telehealth services are becoming more common, giving patients better access to care and consultation from specialists, especially in remote areas. The coronavirus pandemic has accelerated the adoption of these services in the US, which may continue even post-pandemic, improving overall patient management. These trends indicate a dynamic landscape in the US Glioblastoma Market as new technologies and approaches continue to emerge, driven by a collective effort to enhance patient outcomes in this challenging area of oncology.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Glioblastoma Market Drivers**

### Increasing Incidence of Glioblastoma

The increasing incidence of glioblastoma is one of the primary drivers of the US Glioblastoma Market Industry. According to data from the American Cancer Society, there were approximately 24,000 new cases of glioblastoma in the United States in 2021, and this number is projected to rise by about 1.5% annually. This growth is primarily driven by an aging population, as glioblastoma is more common in individuals over the age of 55. Additionally, the National Cancer Institute has reported that glioblastomas account for nearly 15% of all primary brain tumors, highlighting the significant demand for effective treatments and interventions.

As major pharmaceutical companies invest heavily in Research and Development to develop novel therapies, the US Glioblastoma Market is expected to see substantial expansion through the coming decades.

### Advancements in Treatment Modalities

Rapid advancements in treatment modalities, such as immunotherapy and targeted therapies, are significantly bolstering the US Glioblastoma Market Industry. The FDA has recently approved several new treatment options that enhance survival rates and reduce side effects for glioblastoma patients. It is estimated that 8% of glioblastoma patients are treated with new therapies each year, improving patient outcomes. Furthermore, organizations like the National Institutes of Health are heavily investing in innovative research that focuses on personalized medicine approaches for cancer therapy.
This influx of cutting-edge treatment options is expected to drive market growth as healthcare providers increasingly adopt these new methods.

### Growing Focus on Research and Development

The growing focus on Research and Development (R&D) in the oncology sector is a significant catalyst for the US Glioblastoma Market Industry. The National Institutes of Health reported an increase in cancer research funding to over 6 billion USD in recent years, specifically targeting malignant brain tumors like glioblastoma. This surge in funding has led to over 300 ongoing clinical trials, reflecting the commitment to discovering novel therapies and improving patient care.
As pharmaceutical companies and research institutions collaborate on innovative solutions, the impact on treatment availability and patient prognosis will likely drive market growth in the upcoming years

## **US Glioblastoma Market Segment Insights:**

### **Glioblastoma Maaket Treatment Type Insights**

The US Glioblastoma Market showcases a robust landscape within the Treatment Type segment, comprising various therapeutic approaches tailored to combat this aggressive brain cancer. Notably, Surgery stands out as a critical intervention primarily aimed at tumor removal, which can provide immediate relief and significantly improve survival rates. In the realm of Radiation Therapy, advancements are making it a key player in managing glioblastoma, particularly in conjunction with surgical procedures, as it targets residual tumor cells to minimize recurrence risks.

Chemotherapy, relying on powerful drug regimens, remains a cornerstone in the treatment protocol, delivering systemic therapy to combat cancer both in the localized and metastatic phases. Examining targeted therapy reveals a focus on specific molecular alterations associated with glioblastoma, offering a more personalized approach that aligns treatment with the genetic makeup of the tumor, which enhances efficacy while reducing collateral damage to healthy cells.

On the other hand, Immunotherapy has gained traction in recent years as a promising avenue, exploiting the body's immune system to recognize and destroy cancer cells and showing encouraging results as novel agents are introduced into clinical practice. Each of these treatment modalities contributes to a comprehensive strategy against glioblastoma, reflecting the complexity of the disease and the continual evolution of therapeutic options available in the US Glioblastoma Market.

Together, these treatment types offer hope and options for patients, fostering a dynamic environment driven by clinical trials, research, and innovation aimed at improving patient outcomes and survival rates, highlighting the importance of a multi-faceted approach toward treatment in this challenging market. The US Glioblastoma Market develops in response to patient needs and research advancements, showcasing an ever-evolving landscape of treatment type options that respond to the increasing demands for effective and targeted therapies.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Glioblastoma Market Drug Type Insights**

The Drug Type segment of the US Glioblastoma Market plays a critical role in the treatment landscape for this aggressive form of brain cancer. Temozolomide remains a cornerstone therapy, known for its oral administration and favorable efficacy profile, making it a frequent choice among clinicians. Bevacizumab, with its mechanism as an angiogenesis inhibitor, has gained prominence for its potential to improve symptom control and prolong progression-free survival in patients. Carmustine and Lomustine are alkylating agents that have historically provided value in chemotherapy regimens, addressing challenges related to tumor recurrence.

Nivolumab, an immune checkpoint inhibitor, represents a newer therapeutic approach that has shown promise in enhancing immune response against glioblastoma cells. The interplay of these treatments addresses multifactorial factors such as tumor biology and patient-specific variables. As a result, this segment demonstrates significant potential for innovation and growth, with ongoing research focusing on combination therapies and enhancing treatment efficacy. Overall, the Drug Type segment continues to evolve, supporting a diverse range of treatment options that can be tailored to individual patient needs, thus contributing positively to the US Glioblastoma Market dynamics.

### **Glioblastoma Market Distribution Channel Insights**

The Distribution Channel segment of the US Glioblastoma Market plays a crucial role in ensuring effective access to treatments for patients battling this aggressive type of brain cancer. Within this framework, Hospital Pharmacies are vital, as they directly cater to patients admitted to healthcare facilities, offering specialized care and immediate access to medication. Retail Pharmacies contribute significantly to patient convenience, providing necessary treatments in community settings. Additionally, Online Pharmacies are gaining traction as they enhance accessibility, particularly for patients who may have mobility issues or live in remote areas.

Specialty Pharmacies focus on specific high-cost medications and offer comprehensive patient support, including counseling and adherence programs. This varied distribution approach caters to the diverse needs of patients and healthcare providers, fostering a comprehensive treatment experience. Overall, the segmentation within the US Glioblastoma Market highlights the importance of tailored distribution strategies in improving patient outcomes and driving the market forward. The evolving trends within these channels reflect the heightened emphasis on patient-centric care and the increasing role of technology in medication distribution.

### **Glioblastoma Market End User Insights**

The End User segment of the US Glioblastoma Market is crucial in delivering care and advancing treatment options for patients affected by this aggressive form of brain cancer. Hospitals play a dominant role in the management of glioblastoma, equipped with advanced technologies and a multidisciplinary team of specialists focused on precision medicine and patient-centered care. Clinical Research Organizations are pivotal in facilitating clinical trials that are essential for developing novel therapies and understanding the efficacy of existing treatments, thereby driving innovation in the treatment landscape.

Homecare Settings have gained significance as they provide supportive care to patients outside traditional clinical environments, allowing for improved quality of life and personalized support. This segment's robust structure contributes to enhancing treatment accessibility and maintaining continuity of care, addressing the individual needs of glioblastoma patients while also dealing with the challenges inherent in managing such a complex disease. The overall dynamics of this segment reflect broader trends in healthcare, emphasizing the importance of collaboration, patient engagement, and the move towards integrated care models that can address the multifaceted challenges of glioblastoma treatment in the US.

## **US Glioblastoma Market Key Players and Competitive Insights:**

The US Glioblastoma Market is characterized by a dynamic landscape marked by intense competition among pharmaceutical companies aiming to develop innovative treatments for this aggressive form of brain cancer. Glioblastoma, known for its poor prognosis and rapid progression, presents significant challenges for patients and healthcare providers alike. As such, the market has seen a surge in research and development activities, with companies investing heavily in novel therapeutics, including targeted therapies, immunotherapies, and combination treatments. Competitive insights reveal a marketplace that not only values product differentiation but also emphasizes collaboration, strategic partnerships, and a keen understanding of regulatory pathways.

The presence of both established players and startups lends itself to a competitive atmosphere where agility and innovation are paramount. Merrimack Pharmaceuticals has established a strong position within the US Glioblastoma Market through its focus on developing breakthrough therapies specifically tailored for complex oncological conditions. The company’s strengths lie in its robust pipeline and expertise in precision medicine, which enhances its ability to target glioblastoma effectively. Additionally, Merrimack's commitment to exploring novel treatment combinations allows for the potential to enhance patient outcomes, setting the stage for competitive advantage.

The firm has also sought partnerships and collaborations that further amplify its reach and resources, thereby reinforcing its market presence. By leveraging advanced research capabilities, Merrimack Pharmaceuticals aims to continue contributing significantly to the treatment landscape for glioblastoma, capitalizing on its strong foundation in drug development and innovation. Checkmate Pharmaceuticals offers a compelling overview of its role in the US Glioblastoma Market with its focus on immuno-oncology approaches aimed at optimizing the body’s immune response against tumors. The company’s primary strength is rooted in its proprietary platform technologies that enable the development of novel therapies for glioblastoma and other malignancies.

Checkmate Pharmaceuticals has made considerable strides in clinical developments, which speak to its commitment to addressing unmet medical needs in the glioblastoma space. Its key products through advanced clinical programs position it well against competitors, while strategic mergers and acquisitions have bolstered its operational capabilities and expanded its portfolio. By enhancing its product line and increasing market presence through strategic initiatives, Checkmate Pharmaceuticals is poised to influence the treatment paradigm for glioblastoma, thereby shaping the competitive dynamics within the US market landscape.

### **Key Companies in the US Glioblastoma Market Include:**

## **US Glioblastoma Market Industry Developments**

Recent developments in the US Glioblastoma Market have seen significant advancements, particularly in treatment approaches involving companies like Genentech, Novartis, and Merck. In June 2023, Merck announced promising results from a clinical trial using pembrolizumab for combination treatment in glioblastoma patients, enhancing their market position. Meanwhile, Checkmate Pharmaceuticals has continued to make strides in immunotherapy for glioblastoma, with ongoing studies showing potential efficacy in late-stage patients. Notably, Eli Lilly's recent acquisition of a smaller biotech firm in October 2023 aims to bolster its pipeline for central nervous system tumors, including glioblastoma.

The US market is also witnessing increased funding from the National Institutes of Health for glioblastoma research, reflecting a push for innovative therapies and drugs. Over the past two years, Xencor's collaboration with Bristol-Myers Squibb in exploring antibody-drug conjugates has further underscored the market's active research environment. This momentum is contributing to a growing market valuation and potentially altering treatment paradigms, with fierce competition among established players such as Roche and ImmunityBio highlighting shifts in strategic focus and resource allocation within the sector.

## **Glioblastoma Market Segmentation Insights**

### **Glioblastoma Market Treatment Type Outlook**

- - **Surgery** - **Radiation Therapy** - **Chemotherapy** - **Targeted Therapy** - **Immunotherapy**

### **Glioblastoma Market Drug Type Outlook**

- - **Temozolomide** - **Bevacizumab** - **Carmustine** - **Nivolumab** - **Lomustine**

### **Glioblastoma Market Distribution Channel Outlook**

- - **Hospital Pharmacy** - **Retail Pharmacy** - **Online Pharmacy** - **Specialty Pharmacy**

**Glioblastoma Market End User Outlook**

- - **Hospitals** - **Clinical Research Organizations** - **Homecare Settings**

## Market Drivers

### Rising Awareness and Advocacy

The growing awareness and advocacy surrounding glioblastoma are crucial drivers for the glioblastoma market. Non-profit organizations and patient advocacy groups are increasingly active in raising awareness about the disease, leading to enhanced public understanding and support for research initiatives. Campaigns aimed at educating the public about symptoms and treatment options have the potential to increase early diagnosis rates, which may improve patient outcomes. Furthermore, heightened awareness can lead to increased funding for research and development, as more stakeholders recognize the need for effective therapies. This shift in public perception is likely to create a more favorable environment for the glioblastoma market, encouraging investment and innovation.

### Government Initiatives and Funding

Government initiatives aimed at combating glioblastoma are playing a pivotal role in shaping the glioblastoma market. Increased funding for research programs and clinical trials has been observed, with federal agencies allocating millions of dollars to support innovative studies. For example, the National Institutes of Health (NIH) has prioritized brain cancer research, which is expected to enhance the understanding of glioblastoma and lead to the development of new therapies. This financial backing not only encourages academic institutions and biotech companies to pursue groundbreaking research but also fosters collaboration across various sectors. As a result, the glioblastoma market is likely to benefit from a surge in novel treatment options and improved patient outcomes.

### Advancements in Treatment Modalities

Innovations in treatment modalities are significantly influencing the glioblastoma market. The introduction of novel therapies, including targeted therapies and immunotherapies, has transformed the treatment landscape. For instance, the FDA has approved several new agents that have shown promise in extending survival rates. The market for glioblastoma treatments is projected to reach approximately $3 billion by 2026, reflecting the growing investment in research and development. These advancements not only enhance patient outcomes but also attract substantial funding from both public and private sectors, further propelling the market forward. As new treatment options emerge, the competitive dynamics within the glioblastoma market are likely to evolve, fostering innovation and improving patient care.

### Increasing Incidence of Glioblastoma

The rising incidence of glioblastoma in the US is a critical driver for the glioblastoma market. Recent statistics indicate that approximately 3.2 cases per 100,000 individuals are diagnosed annually, with a notable increase in the aging population. This demographic shift is likely to contribute to a higher prevalence of glioblastoma, thereby intensifying the demand for effective treatment options. As the number of patients grows, pharmaceutical companies are compelled to invest in research and development, leading to a more competitive landscape. The increasing incidence not only drives the need for innovative therapies but also stimulates market growth, as healthcare providers seek to address the challenges posed by this aggressive form of brain cancer.

### Emerging Biomarkers and Diagnostic Tools

The identification of emerging biomarkers and the development of advanced diagnostic tools are transforming the glioblastoma market. These innovations facilitate earlier and more accurate diagnosis, which is essential for effective treatment planning. The integration of molecular profiling and imaging technologies is enabling healthcare providers to tailor therapies to individual patients, thereby improving outcomes. As the demand for precision medicine grows, the market for diagnostic tools is expected to expand significantly, potentially reaching $1 billion by 2027. This trend not only enhances the understanding of glioblastoma but also drives the development of targeted therapies, creating a synergistic effect that propels the glioblastoma market forward.

## Future Outlook

The [Glioblastoma Market](https://www.marketresearchfuture.com/reports/glioblastoma-market-8307) is projected to grow at a 5.94% CAGR from 2025 to 2035, driven by advancements in treatment options, increased research funding, and rising patient awareness.

**New opportunities:**

- Development of personalized medicine solutions for glioblastoma patients. Expansion of telehealth services for remote patient monitoring and consultations. Investment in innovative drug delivery systems to enhance treatment efficacy.

By 2035, the glioblastoma market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Treatment Type: Surgery (Largest) vs. Immunotherapy (Fastest-Growing)

In the US glioblastoma market, surgery holds the largest market share among treatment types, with a significant portion of patients undergoing surgical procedures as their first line of treatment. This is largely due to the aim of tumor resection, which is considered a critical approach in managing glioblastoma. Following surgery, radiation therapy and chemotherapy also maintain substantial shares, while targeted therapy and immunotherapy are emerging with increasing acceptance amongst healthcare providers and patients alike.

Growth trends in the treatment type segment are being driven by advancements in technology and a better understanding of glioblastoma biology. The rise of immunotherapy as a promising treatment option is contributing to its rapid growth, often seen as a beacon of hope for improved patient outcomes. Additionally, ongoing clinical research is paving the way for novel therapies that cater to patients' needs, enhancing the variety of available treatment options and driving market expansion.

Surgery (Dominant) vs. Immunotherapy (Emerging)

Surgery remains the dominant treatment choice in the US glioblastoma market, primarily due to its potential to remove a significant portion of the tumor. This surgical intervention is often accompanied by postoperative therapies, such as radiation and chemotherapy, to optimize patient prognosis. On the other hand, immunotherapy is gaining traction as an emerging treatment, offering patients a less conventional approach that harnesses the immune system to combat cancer cells. As research progresses, immunotherapy is being increasingly integrated into treatment plans, often in conjunction with standard therapies, leading to significant interest and investment in this area. The evolving landscape of glioblastoma treatment indicates a shift towards personalized medicine, where both surgery and immunotherapy play crucial roles in patient management.

### By Drug Type: Temozolomide (Largest) vs. Bevacizumab (Fastest-Growing)

In the US glioblastoma market, Temozolomide dominates with a significant market share, representing the cornerstone of treatment. Its established efficacy and usage make it the most prevalent drug among oncologists, subsequently establishing its leading position in the market. Bevacizumab follows but is gaining traction quickly among healthcare providers due to its novel mechanisms and the potential for improved patient outcomes. 

The growth trends in this segment reveal an increasing interest in targeted therapies and combinations with immunotherapies. This is largely driven by ongoing clinical trials showcasing improved survival rates and extended quality of life for patients. Furthermore, rising awareness and diagnosis rates are propelling the demand for innovative treatments, making Bevacizumab a key player in future market dynamics.

Temozolomide (Dominant) vs. Carmustine (Emerging)

Temozolomide is established as the dominant drug in the US glioblastoma market due to its extensive clinical validation and standard treatment protocols. It is frequently the first-line therapy for glioblastoma patients, leading to its high adoption rates. In contrast, Carmustine, while less commonly used, is emerging due to its unique formulation and efficacy in particular patient populations. As treatment regimens evolve, Carmustine is being reconsidered, especially in cases where Temozolomide is not effective, allowing it to capture a niche but growing segment of the market. This duality reflects a changing landscape in treatment approaches, as oncologists seek to customize care to meet individual patient needs.

### By Distribution Channel: Hospital Pharmacy (Largest) vs. Specialty Pharmacy (Fastest-Growing)

In the US glioblastoma market, the distribution of market share among different channels reveals that Hospital Pharmacy takes the lead, being the most prevalent channel for the dispensation of glioblastoma treatments. Following closely are Retail Pharmacies, which serve a significant portion of patients; however, they do not match the volume handled by Hospital Pharmacies. Online Pharmacies and Specialty Pharmacies, while smaller in share, play crucial roles in catering to specific patient needs and preferences. 

Looking at growth trends, Specialty Pharmacy is emerging as the fastest-growing distribution channel within the US glioblastoma market. The increase in targeted therapeutics and personalized medicine drives this growth, as Specialty Pharmacies specialize in complex treatment regimens, providing specialized support that traditional pharmacies may not offer. Simultaneously, the convenience of Online Pharmacies is contributing to shifts in consumer behavior, appealing to patients seeking easier access to medication delivery.

Hospital Pharmacy (Dominant) vs. Specialty Pharmacy (Emerging)

Hospital Pharmacies dominate the US glioblastoma market due to their integrated healthcare model, offering access to comprehensive patient care and timely availability of treatments. They are strategically positioned within hospital systems, allowing for immediate availability of critical medications and fostering collaboration with oncologists for optimal patient management. On the other hand, Specialty Pharmacies are emerging as vital players by focusing on high-cost, complex therapies, offering personalized services such as patient education and adherence monitoring. They cater to patients with specific needs, ensuring they receive the tailored support required for effective treatment management. This duality enhances treatment outcomes and patient satisfaction in the US glioblastoma market.

### By End User: Hospitals (Largest) vs. Clinical Research Organizations (Fastest-Growing)

In the US glioblastoma market, the distribution of market share across end user segments reveals hospitals as the most dominant force, capturing a significant portion of treatment and management services. Clinical research organizations, while smaller in share compared to hospitals, are rapidly increasing their role as they cater to the growing need for innovative treatments and clinical trials.

The growth trends for these segments are primarily driven by advancements in treatment methodologies and a rising emphasis on research and clinical trials. Hospitals are leveraging cutting-edge therapies and increasing patient volumes, while clinical research organizations benefit from a shift toward personalized medicine and the urgency for fast-tracking glioblastoma research. This dual momentum creates a dynamic environment for both segments as they adapt to evolving market demands.

Hospitals (Dominant) vs. Clinical Research Organizations (Emerging)

Hospitals serve as the cornerstone of glioblastoma care, offering comprehensive services that range from diagnosis to advanced treatment protocols. They facilitate access to multidisciplinary teams ensuring holistic patient management. Their established infrastructure, coupled with experienced healthcare professionals, positions them effectively to handle the complexities of glioblastoma treatment. In contrast, clinical research organizations represent the emerging force focused on innovation. Their agility allows them to adapt swiftly to new research findings and clinical trial developments, playing a critical role in advancing treatment options. They foster collaborations with pharmaceutical companies and research institutes, focusing on groundbreaking therapies that may redefine glioblastoma care in the near future.

## Competitive Benchmarking

The glioblastoma market exhibits a complex competitive landscape characterized by rapid innovation and strategic maneuvering among key players. Major companies such as Bristol-Myers Squibb (US), Roche (CH), and Merck & Co (US) are at the forefront, each leveraging unique strategies to enhance their market presence. Bristol-Myers Squibb (US) focuses on expanding its immunotherapy portfolio, while Roche (CH) emphasizes precision medicine through targeted therapies. Merck & Co (US) is investing heavily in research and development, particularly in combination therapies, which are anticipated to improve patient outcomes. Collectively, these strategies foster a dynamic environment where innovation and therapeutic advancements are paramount.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the glioblastoma market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they drive trends in research, development, and commercialization of new therapies, thereby shaping the overall market dynamics.
In October Roche (CH) announced the initiation of a pivotal clinical trial for its novel targeted therapy aimed at glioblastoma patients with specific genetic mutations. This strategic move underscores Roche's commitment to precision medicine and its potential to significantly alter treatment paradigms. By focusing on genetic markers, Roche may enhance treatment efficacy and patient outcomes, positioning itself as a leader in personalized therapies within the glioblastoma space.
In September Merck & Co (US) revealed promising results from a Phase III trial evaluating a combination of its immunotherapy with a novel chemotherapy agent. This development is crucial as it not only reinforces Merck's position in the market but also highlights the growing trend towards combination therapies that may offer improved survival rates for glioblastoma patients. The implications of this trial could lead to new treatment protocols and further solidify Merck's competitive edge.
In August Bristol-Myers Squibb (US) entered into a strategic partnership with a biotech firm specializing in gene therapy for glioblastoma. This collaboration aims to accelerate the development of innovative treatment options, reflecting a broader trend of alliances in the industry. Such partnerships are likely to enhance research capabilities and expedite the delivery of novel therapies to the market, thereby fostering a more competitive landscape.
As of November the glioblastoma market is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to tackle complex challenges in treatment development. Looking ahead, competitive differentiation is expected to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to enhanced patient care and improved therapeutic outcomes.

## Recent News & Developments

Recent developments in the US Glioblastoma Market have seen significant advancements, particularly in treatment approaches involving companies like Genentech, Novartis, and Merck. In June 2023, Merck announced promising results from a clinical trial using pembrolizumab for combination treatment in glioblastoma patients, enhancing their market position. Meanwhile, Checkmate Pharmaceuticals has continued to make strides in immunotherapy for glioblastoma, with ongoing studies showing potential efficacy in late-stage patients. Notably, Eli Lilly's recent acquisition of a smaller biotech firm in October 2023 aims to bolster its pipeline for central nervous system tumors, including glioblastoma.

The US market is also witnessing increased funding from the National Institutes of Health for glioblastoma research, reflecting a push for innovative therapies and drugs. Over the past two years, Xencor's collaboration with Bristol-Myers Squibb in exploring antibody-drug conjugates has further underscored the market's active research environment. This momentum is contributing to a growing market valuation and potentially altering treatment paradigms, with fierce competition among established players such as Roche and ImmunityBio highlighting shifts in strategic focus and resource allocation within the sector.

## Report Scope

| MARKET SIZE 2024 | 714.14(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 756.56(USD Million) |
| MARKET SIZE 2035 | 1347.24(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.94% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Bristol-Myers Squibb (US), Roche (CH), Merck & Co (US), Novartis (CH), Eli Lilly and Company (US), Amgen (US), AstraZeneca (GB), Regeneron Pharmaceuticals (US), Pfizer (US) |
| Segments Covered | Treatment Type, Drug Type, Distribution Channel, End User |
| Key Market Opportunities | Advancements in targeted therapies and immunotherapies present growth opportunities in the glioblastoma market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the glioblastoma market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US glioblastoma market in 2024?**
A: The overall market valuation was 714.14 $ Million in 2024.

**Q: What is the projected market valuation for the US glioblastoma market by 2035?**
A: The projected valuation for 2035 is 1347.24 $ Million.

**Q: What is the expected CAGR for the US glioblastoma market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 5.94 %.

**Q: Which treatment type had the highest valuation in the US glioblastoma market in 2024?**
A: Chemotherapy had the highest valuation, ranging from 200.0 to 400.0 $ Million.

**Q: What are the key players in the US glioblastoma market?**
A: Key players include Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Eli Lilly and Company, Amgen, AstraZeneca, Regeneron Pharmaceuticals, and Pfizer.

**Q: What was the valuation range for immunotherapy in the US glioblastoma market in 2024?**
A: Immunotherapy had a valuation range of 164.14 to 197.24 $ Million.

**Q: Which drug type is projected to have the highest valuation in the US glioblastoma market by 2035?**
A: Temozolomide is projected to have the highest valuation, ranging from 300.0 to 600.0 $ Million.

**Q: What distribution channel had the highest valuation in the US glioblastoma market in 2024?**
A: Specialty Pharmacy had the highest valuation, ranging from 250.0 to 447.24 $ Million.

**Q: What is the projected valuation for hospitals as an end user in the US glioblastoma market by 2035?**
A: The projected valuation for hospitals as an end user is expected to range from 428.0 to 800.0 $ Million.

**Q: How does the market valuation for clinical research organizations compare to hospitals in 2024?**
A: In 2024, clinical research organizations had a valuation range of 143.14 to 250.0 $ Million, significantly lower than hospitals.

**Q: What will be the market value of the US Glioblastoma Market in 2035?**
A: In 2035, the US Glioblastoma Market is projected to reach a value of 1,025.18 million USD.

**Q: What treatment type is expected to dominate the US Glioblastoma Market by 2035?**
A: Surgery is expected to dominate the US Glioblastoma Market, reaching approximately 323.45 million USD by 2035.

**Q: Which key players are currently leading the US Glioblastoma Market?**
A: Major players in the US Glioblastoma Market include Merrimack Pharmaceuticals, Genentech, Novartis, and Merck.

**Q: How much is the Radiation Therapy segment valued at in 2024?**
A: The Radiation Therapy segment of the US Glioblastoma Market is valued at 121.67 million USD in 2024.

**Q: What is the market size for Chemotherapy in the US Glioblastoma Market in 2035?**
A: The Chemotherapy segment is projected to reach 272.34 million USD in the US Glioblastoma Market by 2035.

**Q: What challenges are influencing growth in the US Glioblastoma Market?**
A: Challenges in the US Glioblastoma Market include the high treatment costs and complexities of therapy management.

**Q: What opportunities exist for growth in the US Glioblastoma Market?**
A: Opportunities for growth in the US Glioblastoma Market include advancements in targeted and immunotherapy treatments.

**Q: How is the Immunotherapy segment expected to perform by 2035?**
A: The Immunotherapy segment is expected to grow to approximately 79.15 million USD by 2035 in the US Glioblastoma Market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-glioblastoma-market-18018*